The latest myeloma news
Unlocking the potential of targeted therapies for multiple myeloma
Multiple myeloma (MM) is a complex haematological malignancy with significant unmet needs. While conventional therapies…
Browsing: Myeloma
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma
On July 30, 2024, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj in combination with…
Blood test may guide use of multiple myeloma immunotherapy
A simple blood test that measures the number of lymphocytes, a type of white blood…
EHA 2024: Updated linvoseltamab data showcase continued deepening of responses in patients with heavily pre-treated multiple myeloma
The 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in…
ASCO 2024: Adding belantamab mafodotin to multiple myeloma treatment combinations slows disease progression or death
According to a new study, adding belantamab mafodotin to pomalidomide and dexamethasone for the treatment…
Recent FDA committee vote could speed multiple myeloma drug approval
A U.S. Food and Drug Administration committee voted unanimously in April to approve a new…
New study points to racial and social barriers that block treatment for multiple myeloma
A study reveals persistent racial and social disparities preventing access to autoHCT in the USA,…
Biomarkers identified for successful treatment of bone marrow tumours
CAR T cell therapy has proven effective in treating various haematological cancers. However, not all…
AACR 2024: Linvoseltamab shows high response rate in heavily pre-treated multiple myeloma
The Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM)…
Research identifies promising drug combination for multiple myeloma treatment
RCSI research has found that venetoclax, a medication currently approved for leukaemia, has benefits for…